This study will enroll patients ages 18 and over who are in one of the following groups 1) taking a GLP-1 receptor agonist medication 2) not taking a GLP-1 receptor agonist (control group), are undergoing EGS and have appropriately fasted. Study data will be collected in the form of qualitatively observing whether the stomach is empty as expected, or contains solid or clinically relevant liquid contents.

Inclusion Criteria

• Adults 18 years of age and older presenting for esophagogastroduodenoscopy (EGD)

• One of the following groups:

  • GLP-1 receptor agonist cohort: active treatment with any GLP-1 receptor agonist therapy within prior 30 days
  • Control cohort: not taking a GLP-1 receptor agonist medication

• Appropriately fasted per ASA Fasting Guidelines

Exclusion Criteria

• Simultaneous bowel preparation/planned dual endoscopy with colonoscopy
• Any pre-planned alteration to standard fasting guidelines (ASA NPO guidelines)
• Emergency endoscopic procedure
• Concern for active GI bleeding
• Food impaction/foreign body as indication for procedure
• Gastric outlet obstruction/bowel obstruction
• Achalasia
• Zenker's diverticulum
• History of esophageal or gastric surgery
• Active pregnancy
• Chronic daily opioid therapy ≥ 15 MMEs per day
• Prokinetic agent use (i.e. metoclopramide)
• Inability or unwillingness of subject to give informed consent

This study will consist of patients who have appropriately fasted, and are scheduled for an esophagogastroduodenoscopy (EGD). Patients will fall in to two groups: 1) taking a GLP-1 receptor agonist or 2) not taking a receptor agonist medication.